Physician profile
Susan M Flick
NPI 1710175179
$130,844.18
in general payments reported to CMS, 2019-2025
38 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24K · 2022: $51K · 2023: $38K · 2024: $17K · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $19K · Food and Beverage: $5,858 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,315.00 |
| Travel and Lodging | $19,468.85 |
| Food and Beverage | $5,857.97 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $81,926.23 | 2021-2025 | Lynparza, Farxiga, Airsupra |
| Emd Serono, INC. | $41,625.61 | 2021-2024 | Bavencio |
| Astellas Pharma US INC | $1,786.95 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $1,379.66 | 2021-2025 | |
| Abbvie INC. | $734.10 | 2023-2025 | |
| Rochester Medical Corporation | $637.45 | 2021-2022 | |
| Amgen INC. | $575.64 | 2021-2025 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $343.88 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $264.68 | 2024-2025 | Kisunla, Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $220.00 | 2023-2024 | Nexletol, Nexlizet |
| Myovant Sciences INC. | $175.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $152.32 | 2022-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Exact Sciences Corporation | $95.33 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.94 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $83.26 | 2023-2024 | Shingrix, Arexvy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.78 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $60.35 | 2023-2025 | Gemtesa |
| Bausch Health US, LLC | $56.01 | 2022-2023 | Aplenzin |
| Radius Health, INC. | $54.99 | 2023-2025 | Tymlos |
| Antares Pharma, INC. | $50.00 | 2022 | |
| Seqirus USA INC | $44.40 | 2022-2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $43.45 | 2022-2024 | Trintellix |
| Dexcom, INC. | $38.82 | 2023-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $35.70 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.92 | 2023-2025 | |
| Tolmar, INC. | $34.42 | 2023-2024 | |
| Axsome Therapeutics, INC. | $33.23 | 2024-2025 | Auvelity |
| Philips North America LLC | $26.96 | 2023 | |
| Coloplast Corp | $24.31 | 2021 | |
| Foundation Medicine, INC. | $21.15 | 2023 | Foundationone Cdx |
| Teva Pharmaceuticals USA, INC. | $19.74 | 2024 | Ajovy |
| Cashflow Solutions, LLC | $18.60 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Halozyme INC | $17.81 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $17.31 | 2022 | |
| Endo Pharmaceuticals INC. | $17.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.22 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Flick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.